Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m. ET.
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005732/en/
Contacts
Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com
Source: Pipeline Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20200528005732/en
